

"Express Mail" mailing label number EL576623106US

Date of Deposit September 18, 2000.

Case No. 8642/99

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

12-1-00  
#2  
JP  
JCS64 U.S. P.P.  
09/663889  
09/18/00

In re Application of:	
Nabel et al.	
Serial No.: Not Yet Assigned	Examiner: P. Paras
Filed: Herewith	Group Art Unit: 1635
For: KITS FOR SITE-SPECIFICALLY TRANSFORMING CELLS IN VIVO	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Preliminary to the examination of the above-identified application, Applicants wish to bring to the attention of the Examiner the references identified in the following list and on the attached form PTO-1449. These references were previously cited in the related applications, Appln. No. 08/533,942 now U.S. Patent No. 5,863,904, issued January 26, 1999, Appl. No. 09/031,572, now U.S. Patent No. 6,057,300, issued May 2, 2000, and Appln. No. 09/426,325 of which this application is a continuation. Thus, we are not enclosing copies of these references. However, if the Examiner should require copies, Applicants ask that the Examiner contact the undersigned attorney to request them.

## U.S. PATENT DOCUMENT

<u>PATENT NUMBER</u>	<u>DATE</u>	<u>INVENTOR</u>
5,693,622	December 1997	Wolff et al.
5,672,508	September 1997	Gyuris et al.

## FOREIGN PATENT DOCUMENTS

<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>
WO 94/09135	April 1994	WIPO
WO 95/18824	July 1995	WIPO
WO 96/25507	August 1996	WIPO

## OTHER PUBLICATIONS

- Leslie A. Leinwand et al., *Trends Cardiovasc. Med.*, Vol. 1, No. 7, pp. 271-275 (1991).
- George Palade, *Science*, Vol. 189, pp. 347-357 (Aug. 1975).
- Bloom et al., *A Textbook of Histology*, Eleventh Edition, p. 83, p. 279 and p. 51 (1986).
- Richard N. Kitsis et al., *Proc. Natl. Acad. Sci. USA*, Vol. 88, pp. 4138-4142 (May 1991).
- Eliav Barr et al., *Science*, Vol. 254, pp. 1507-1509 (Dec. 1991).
- Hua Lin et al., *Circulation*, Vol. 82, pp. 2217-2221 (Dec. 1990).
- Jyotsna Dhawan et al., *Science*, Vol. 254, pp. 1509-1512 (Dec. 1991).
- Gyula Acsadi et al., *The New Biologists*, Vol. 3, No. 1, pp. 71-81 (Jan. 1991).
- Peter M. Buttrick et al., *Circulation Research*, Vol. 70, No. 1, pp. 193-198 (Jan. 1992).
- Gorman et al., *Science*, Vol. 221, pp. 551-553 (1983).
- Michael S. Parmacek et al., *The Journal of Biological Chemistry*, Vol. 265, No. 26, pp. 15970-15976 (1990).
- Peter G. Anderson et al., *J. Cell Biochem.*, (Suppl.), Vol. 13, Part E, p. 176 (1989).
- T.A. Partridge et al., *Nature*, Vol. 337, pp. 176-179 (Jan. 1989).
- Jon A. Wolff et al., *Science*, Vol. 247, pp. 1465-1468 (Mar. 1990).
- Leiden et al., *Circulation*, Vol. 82, p. 82 (1990) Abstract 0423.

Buttrick et al., *Circulation*, Vol. 82, p. 82 (1990) Abstract 0424.

Marshall, *Science*, 269: 1050-1055, 1995.

Miller et al., *FASEB J.*, 9: 190-199, 1995.

Culver et al., *TIG*, 10(5), 174-178, 1994.

Hodgson, *Exp. Opin. Ther. Pat.*, 5(5): 459-468, 1995.

Lafont et al., *Lancet*, 346: 1442-1443, 1995.

Etienne-Julian et al., The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker, *Journal of General Virology* 73: 3251-3255, 1992.

Jolly, Viral vector systems for gene therapy, *Cancer Gene therapy*, 1:1,51-64, 1994.

Zakut et al., The tumor suppression function of p21 Waf is contained in its N-terminal half, *Oncogene*, 11:393-395, Jul. 1995.

Indolfi et al., Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo, *Nature Medicine*, 1:(6) 541-5, Jun. 1995.

Junjie Chen, et al., "Separate Domains of p21 Involved in the Inhibition of CDK Kinase and PCNA", *Nature*, Vol. 374, pp. 386-388, Mar. 23, 1995.

Aldo Di Leonardo, et al., "DNA Damage Triggers a Prolonged P53-Dependent G1 Arrest and Long-Term Induction of CIP1 in Normal Human Fibroblasts", *Genes & Development*, Vol. 8, pp. 2540-2551, 1994.

Wafik S. El-Deiry, et al., "WAF1/CIP1 is Induced in P53-Mediated G1 Arrest and Apoptosis", *Cancer Research*, Vol. 54, pp. 1169-1174, Mar. 1, 1994.

Wafik S. El-Deiry, et al., "WAF1, A Potential Mediator of P53 Tumor Suppression", *Cell*, Vol. 75, pp. 817-825, Nov. 19, 1993.

Yong Gu, et al., "Inhibition of CDK2 Activity In Vivo by an Associated 20K Regulatory Subunit", *Nature*, Vol. 366, pp. 707-710, Dec. 16, 1993.

J. Wade Harper, et al., "The P21 CDK-Interacting Protein CIP1 is a Potent Inhibitor of G1 Cyclin-Dependent Kinases", *Cell*, Vol. 75, pp. 805-816, Nov. 19, 1993.

Rong Li, et al., "Differential Effects by the P21 CDK Inhibitor on PCNA-Dependent DNA Replication and Repair", *Nature*, Vol. 371, pp. 534-537, Oct. 6, 1994.

Yan Li, et al., "Cell Cycle Expression and P53 Regulation of the Cyclin-Dependent Kinase Inhibitor P21", *Oncogene*, Vol. 9, pp. 2261-2268, 1994.

Shou Waga, et al., "The P21 Inhibitor of Cyclin-Dependent Kinases Controls DNA Replication by Interaction with PCNA", *Nature*, Vol. 369, pp. 574-578, Jun. 16, 1994.

Yue Xiong, et al., "P21 is a Universal Inhibitor of Cyclin Kinases", *Nature*, Vol. 366, pp. 701-704, Dec. 16, 1993.

Hui Zhang, et al., "P21-containing Cyclin Kinases Exist in Both Active and Inactive States", *Genes & Development*, Vol. 8, pp. 1750-1758, 1994.

Kornelia Polyak et al., "Cloning of p27<sup>Kip1</sup>, a Cyclin-Dependent Kinase Inhibitor and a Potential Mediator of Extracellular Antimitogenic Signals", *Cell*, vol. 78, pp. 59-66, July 15, 1994.


Hideo Toyoshima et al., "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21", *Cell*, vol. 78, pp. 67-74, July 15, 1994

It is believed that none of the references, alone or in combination, disclose or suggest the invention claimed. It is Applicants desire, however, to have these references available in the record for both the Examiner and the public to see. Applicants, therefore, request that the Examiner review the entire disclosure of the above discussed references and other information and make the above-described references and other information of record. Because this Information Disclosure Statement is being submitted prior to issuance of the first Office Action, Applicants believe no fees are required. However, if the Commissioner deems otherwise, the Commissioner is authorized to debit any fees from our Deposit Account No. 23-1925.

An action on the merits is requested.

Respectfully submitted,

Dated: September 18, 2000

  
\_\_\_\_\_  
Thomas J. Wrona  
Registration No. 44,410  
Registered Patent Agent

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, IL 60610  
(312)321-4200